Zacks Small Cap Research on MSN
RADX: Interim readout achieves 92% concordance
RADX READ THE FULL RADX RESEARCH REPORT RAD101 Phase IIb Interim Analysis Radiopharm Theranostics (NASDAQ:RADX) reported the primary endpoint for its RAD101 trial in an interim analysis on December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback